Pacira BioSciences, Inc. (PCRX): EBITDA
$110.21M
Year ended 2025-12-31
$105.03M
Trailing 12 months to 2026-06-30
-10.1%
3-year compound annual growth
+10.7%
5-year compound annual growth
+18.1%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $110.21M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $5.41M | -96.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $163.25M | +7.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $151.53M | +27.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $118.47M | +78.8% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $66.26M | +120.4% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $30.06M | +3.4% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $29.08M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$11.10M | n/m | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | -$19.11M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $20.93M | +329.8% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $4.87M | n/m | 2016-02-25, From 2014-01-01 |
| 2013-12-31 | -$47.54M | n/m | 2016-02-25, From 2013-01-01 |
| 2012-12-31 | -$43.65M | n/m | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | -$34.79M | n/m | 2014-02-25, From 2011-01-01 |
| 2010-12-31 | -$18.64M | n/m | 2013-03-07, From 2010-01-01 |
| 2009-12-31 | -$24.40M | n/a | 2012-03-27, From 2009-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $110.21M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $29.28M | -81.9% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $195.90M | n/m |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $45.95M | -66.6% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $78.78M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$500.00M | n/m |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $123.38M | +193.8% |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$25.78M | n/m |
Compare PCRX, SUPN, EBS, CORT side by side · Screen every company in Pharmaceutical Preparations ↗